美国近期短缺药品管理策略与启示

王胜鹏, 王翀, 张弛, 朱炯

中国药事 ›› 2020, Vol. 34 ›› Issue (10) : 1191-1199.

中国药事 ›› 2020, Vol. 34 ›› Issue (10) : 1191-1199. DOI: 10.16153/j.1002-7777.2020.10.011
国外药事

美国近期短缺药品管理策略与启示

  • 王胜鹏, 王翀, 张弛, 朱炯
作者信息 +

On U.S. Current Management Strategy for Drug Shortage and Its Enlightenment

  • Wang Shengpeng, Wang Chong, Zhang Chi, Zhu Jiong
Author information +
文章历史 +

摘要

目的:研究美国短缺药品管理策略,为我国短缺药品管理提供参考。方法:检索FDA官方网站等政府网站查找短缺药品管理相关文件与法规,统计2010-2018年美国短缺药品数据,对美国短缺药品管理策略进行研究。结果:美国组建跨部门短缺药品应对工作组以探索短缺药品应对长效机制,更新了短缺药品管理的政策与程序手册,采取加强药品质量管理、维护市场竞争、确保供应链稳定、机构协作和提倡社会共治等应对措施,注重运用法治思维和法治方式提高短缺药品管理水平。结论:美国短缺药品管理策略和应对计划,对完善我国短缺药品供应保障具有参考价值。

Abstract

Objective: To study the key points of American drug shortage management strategy and provide references for the drug shortage management of China. Methods: The official websites of FDA were retrieved to find related documents, laws and regulations, and the drug shortage data between 2010-2018 were summarized. The drug shortage regulatory strategy was analyzed. Results: An Interagency Drug Shortage Task Force was established to come up with long-term solutions to prevent shortages, and the CDER's Manual of Policies and Procedures for drug shortage management was renewed. Such countermeasures as strengthening drug quality management, maintaining market competition, reassuring supply chain stability, making multi-institutional collaborations and advocating social co-governance, have been taken by the regulatory agency. The application of legal thinking and legal methods to improve the level of drug shortage management was emphasized. Conclusion: The American drug shortage management strategy and the countermeasures are useful in improving the drug shortage management of China.

关键词

短缺药品;管理策略;经验启示;应急管理

Key words

drug shortage; management strategy; experience and inspiration; emergency management

引用本文

导出引用
王胜鹏, 王翀, 张弛, 朱炯. 美国近期短缺药品管理策略与启示[J]. 中国药事, 2020, 34(10): 1191-1199 https://doi.org/10.16153/j.1002-7777.2020.10.011
Wang Shengpeng, Wang Chong, Zhang Chi, Zhu Jiong. On U.S. Current Management Strategy for Drug Shortage and Its Enlightenment[J]. Chinese Pharmaceutical Affairs, 2020, 34(10): 1191-1199 https://doi.org/10.16153/j.1002-7777.2020.10.011

参考文献

[1] FDA.Strategic Plan for Preventing and Mitigating Drug Shortages[EB/OL].(2013-10-01)[2020-04-23].https://www.fda.gov/media/86907/download.
[2] 袁雪丹,傅鸿鹏.全球药品短缺管理及其对我国的启示 [J].中国卫生经济,2016,35(11):60-63.
[3] 刘倩楠,孙静,刘远立.应对药品短缺保障供应的国际实践及对我国的启示[J].中国药房,2017,28(18):2452-2455.
[4] 姚立新,Garth Boehm,郑强.美国药品短缺及FDA采取的应对策略[J].中国新药杂志,2012,21(20):2359-2367.
[5] FDA.FDA is Advancing New Efforts to Address Drug Shortages[EB/OL].(2018-11-19)[2020-04-23].https://www.fda.gov/news-events/fda-voices-perspectives-fdaleadership-and-experts/fda-advancing-new-effortsaddress-drug-shortages.
[6] FDA.The MaPP on Drug Shortage Management[EB/OL].(2018-11-30)[2020-04-23].https://www.fda.gov/media/72447/download.
[7] FDA.Notifying FDA of a Permanent Discontinuance or Interruption in Manufacturing Under Section 506C of the FD&C Act Guidance for Industry[EB/OL].(2020-03-27)[2020-04-23].https://www.fda.gov/media/136486/download.
[8] 国家卫生计生委.关于改革完善短缺药品供应保障机制的实施意见[EB/OL].(2017-06-28)[2020-04-23].http://www.nhc.gov.cn/yaozs/s3581/201706/b430c93e4d084928b02c8bc9fdb eccc0.shtml.
[9] 国务院办公厅.关于改革完善仿制药供应保障及使用政策的意见[EB/OL].(2018-03-21)[2020-04-23].http://www.gov.cn/zhengce/content/2018-04/03/content_527 9546.htm.
[10] 国务院办公厅.国务院办公厅关于进一步做好短缺药品保供稳价工作的意见[EB/OL].(2019-10-11)[2020-04-23].http://www.gov.cn/zhengce/content/2019-10/11/content_5438499.htm.
[11] 王胜鹏,朱炯,高志峰,等.重点短缺药品及供应保障措施探讨[J].中国药事,2018,32(8):1034-1042.
[12] FDA.Agency Drug Shortages Task Force[EB/OL].(2019-10-30)[2020-04-23].https://www.fda.gov/drugs/drugshortages/agency-drug-shortages-task-force.
[13] GAO.Drug Shortages:Better Management of the Quota Process for Controlled Substances Needed;Coordination between DEA and FDA Should Be Improved[EB/OL].(2015-03-04)[2020-04-23].https://www.gao.gov/products/GAO-15-202.
[14] Knopf A.H.R.6:SUPPORT for Patients and Communities Act:The Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act[J].Alcoholism & Drug Abuse Weekly,2018,30(37):4-6.
[15] FTC.Overview of FTC.Actions in Pharmaceutical Products and Distribution[EB/OL].(2019-06-01)[2020-04-23].https://www.ftc.gov/system/files/attachments/competitionpolicy-guidance/overview_pharma_june_2019.pdf.
[16] FTC.FTC Requires Teva to Divest Over 75 Generic Drugs to Settle Competition Concerns Related to its Acquisition of Allergan's Generic Business[EB/OL].(2016-07-27)[2020-04-23].https://www.ftc.gov/news-events/pressreleases/2016/07/ftc-requires-teva-divest-over-75-generic-drugs-rival-firms-settle.
[17] 刘平,扈彩霞.美国公共医疗保险体系设计研究[J].医学与哲学(A),2018,39(11):60-62.
[18] ASPR.Statement of Organization,Functions and Delegations of Authority[J].The Federal Register/FIND,2020,85(030).
[19] 戴建军.美国防科技部门如何促进军民协同创新[N].中国经济时报,2017-08-28(008).
[20] 财政部.美国《减税和就业法案》[EB/OL].(2017-12-22)[2020-04-23].http://www.mof.gov.cn/mofhome/tfs/zhengwuxinxi/zhengcejiedu/201802/t20180209_2810875.html.
[21] FDA.Report on Drug Shortages for Calendar Year 2018[EB/OL].(2019-08-29)[2020-04-23].https://www.fda.gov/media/130561/download.
[22] FDA.Report on Drug Shortages for Calendar Year 2017[EB/OL].(2018-05-16)[2020-04-23].https://www.fda.gov/media/113991/download.
[23] FDA.Drug Shortages:Root Causes and Potential Solutions [EB/OL].(2020-02-21)[2020-04-23].https://www.fda.gov/drugs/drug-shortages/report-drug-shortages-rootcauses-and-potential-solutions.
[24] FDA.To Help Reduce Drug Shortages,We Need Manufacturers to Sell Quality-Not Just Medicine[EB/OL].(2019-10-24)[2020-04-23].https://www.fda.gov/news-events/fda-voices-perspectives-fda-leadershipand-experts/help-reduce-drug-shortages-we-needmanufacturers-sell-quality-not-just-medicine.
[25] FDA.Quality Metrics for Drug Manufacturing[EB/OL].(2019-01-21)[2020-04-23].https://www.fda.gov/drugs/pharmaceutical-quality-resources/quality-metricsdrug-manufacturing.
[26] FDA.2018 Office of Generic Drugs Annual Report[EB/OL].(2019-02-27)[2020-04-23].https://www.fda.gov/drugs/generic-drugs/2018-office-generic-drugs-annualreport.
[27] FTC.Generic Pharmaceutical Association[EB/OL].(2012-08-08)[2020-04-23].https://www.ftc.gov/policy/advisory-opinions/generic-pharmaceutical-association.
[28] FDA.MOU 225-17-015[EB/OL].(2017-12-18)[2020-04-23].https://www.fda.gov/about-fda/domestic-mous/mou-225-17-015.
[29] 于金冉,王宏伟,王艺芳,等.美国药品标识全生命周期管理研究与启示[J].中国药物警戒,2018,15(6):333-338.
[30] ICH工作办公室.关于公开征求ICH指导原则《Q12:产品生命周期管理的技术和法规考虑》意见的通知[EB/OL].(2018-06-29)[2020-04-23].http://www.cde.org.cn/news.do?Method=viewInfoCommon&id= 314464.
[31] 国务院办公厅.中共中央国务院关于深化医疗保障制度改革的意见[EB/OL].(2020-03-05)[2020-04-23].http://www.gov.cn/zhengce/2020-03/05/content_5487407.htm.
[32] 全国人民代表大会.中华人民共和国药品管理法[EB/OL].(2019-08-26)[2020-04-23].http://www.npc.gov.cn/npc/c30834/201908/26a6b28dd83546d79d17f90c6 2e59461.shtml.
[33] 国家药品监督管理局.药品生产监督管理办法[EB/OL].(2020-03-30)[2020-04-23].http://www.nmpa.gov.cn/WS04/CL2077/376152.html.

23

Accesses

0

Citation

Detail

段落导航
相关文章

/